Hassan Aziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hassan Aziz has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Faisal S. Jehan
13 shared publicationsYong K. Kwon
Department of Surgery, UT Southwestern Medical Center, Dallas, Texas
9 shared publicationsApoorve Nayyar
Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa
7 shared publicationsSaba Alvi
Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa
6 shared publicationsSangrag Ganguli
6 shared publications- Timothy Michael Pawlik
Department of Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA
6 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Wiley in Journal of Surgical Oncology
Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era
Hepatic adenomas (HAs) are rare benign liver tumors traditionally associated with young women, yet contemporary epidemiologic trends reveal increasing recognition among men. Historically, universal resection in males has been recommended because of a nearly tenfold increased risk of malignant transformation as reported by Farges et al. in a single‐institution surgical series ; however, advances in molecular profiling and imaging have challenged this paradigm. β‐catenin–activated and inflammatory subtypes account for most cases in men, often associated with anabolic steroid exposure, obesity, or metabolic syndrome. β‐catenin‐activated adenomas—particularly those harboring CTNNB1 exon 3 mutations—demonstrate the strongest correlation with malignant potential. Magnetic resonance imaging with hepatobiliary contrast agents can suggest subtype but lacks perfect accuracy; biopsy offers improved diagnostic precision and enables molecular confirmation. Current ACG and EASL guidelines still endorse routine resection for all hepatic adenomas in males; however, available retrospective data suggest that malignant transformation appears to be uncommon in small (5 cm) lesions lacking exon 3 CTNNB1 mutations; however, this observation is derived from limited, predominantly retrospective data and does not exclude the possibility of malignant transformation in this subgroup. These data support selective, biopsy‐guided surveillance for small, indeterminate tumors within experienced multidisciplinary centers where longitudinal follow‐up is reliable. Resection remains the standard recommendation for large or β‐catenin–mutated adenomas, with minimally invasive surgery demonstrating excellent outcomes. Modern management of hepatic adenomas in men should be individualized, integrating molecular subtype, size, risk factors, and patient context. A multidisciplinary and molecularly informed strategy is essential to optimize outcomes while avoiding unnecessary intervention.
- 18 October 2026
- Published by Wiley in Journal of Surgical Oncology
Open AccessHepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era
Hepatic adenomas (HAs) are rare benign liver tumors traditionally associated with young women, yet contemporary epidemiologic trends reveal increasing recognition among men. Historically, universal resection in males has been recommended because of a nearly tenfold increased risk of malignant transformation as reported by Farges et al. in a single‐institution surgical series ; however, advances in molecular profiling and imaging have challenged this paradigm. β‐catenin–activated and inflammatory subtypes account for most cases in men, often associated with anabolic steroid exposure, obesity, or metabolic syndrome. β‐catenin‐activated adenomas—particularly those harboring CTNNB1 exon 3 mutations—demonstrate the strongest correlation with malignant potential. Magnetic resonance imaging with hepatobiliary contrast agents can suggest subtype but lacks perfect accuracy; biopsy offers improved diagnostic precision and enables molecular confirmation. Current ACG and EASL guidelines still endorse routine resection for all hepatic adenomas in males; however, available retrospective data suggest that malignant transformation appears to be uncommon in small (5 cm) lesions lacking exon 3 CTNNB1 mutations; however, this observation is derived from limited, predominantly retrospective data and does not exclude the possibility of malignant transformation in this subgroup. These data support selective, biopsy‐guided surveillance for small, indeterminate tumors within experienced multidisciplinary centers where longitudinal follow‐up is reliable. Resection remains the standard recommendation for large or β‐catenin–mutated adenomas, with minimally invasive surgery demonstrating excellent outcomes. Modern management of hepatic adenomas in men should be individualized, integrating molecular subtype, size, risk factors, and patient context. A multidisciplinary and molecularly informed strategy is essential to optimize outcomes while avoiding unnecessary intervention.
- 13 October 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (12)
Dose matters: incremental association of perioperative blood transfusion with morbidity and mortality after hepatectomy
- 13 October 2026
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 30 (12)
Dose matters: incremental association of perioperative blood transfusion with morbidity and mortality after hepatectomy
- Open Access
- 30 August 2026
- Published by Wiley in Journal of Surgical Oncology
When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature
Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan. This paper aims to review the incidence, prognostic implications, post‐transplant management, and outcomes of explant pathology in patients with HCC beyond Milan. We conducted a narrative review of the literature focusing on imaging–pathology discrepancies, recurrence risk stratification, immunosuppression strategies, surveillance, and adjuvant therapeutic considerations. A significant proportion of LT recipients had explant findings that exceeded the predicted criteria. These patients are at higher risk of recurrence, particularly those with microvascular invasion and poor differentiation. Currently, no standard adjuvant therapy exists; however, individualized surveillance and immunosuppression optimization, including sirolimus‐based regimens, are reasonable strategies. Prospective studies are needed to define the optimal post‐transplant pathways. Explant‐beyond‐criteria HCC represents a distinct high‐risk population that requires individualized post‐transplant management. While no validated adjuvant therapy exists, risk stratification using tools such as the RETREAT score, immunosuppression optimization with mammalian target of rapamycin (mTOR) inhibitors, and intensified surveillance may improve outcomes. Prospective studies are needed to define the optimal management strategies for this challenging population.
- 30 August 2026
- Published by Wiley in Journal of Surgical Oncology
Open AccessWhen Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature
Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan. This paper aims to review the incidence, prognostic implications, post‐transplant management, and outcomes of explant pathology in patients with HCC beyond Milan. We conducted a narrative review of the literature focusing on imaging–pathology discrepancies, recurrence risk stratification, immunosuppression strategies, surveillance, and adjuvant therapeutic considerations. A significant proportion of LT recipients had explant findings that exceeded the predicted criteria. These patients are at higher risk of recurrence, particularly those with microvascular invasion and poor differentiation. Currently, no standard adjuvant therapy exists; however, individualized surveillance and immunosuppression optimization, including sirolimus‐based regimens, are reasonable strategies. Prospective studies are needed to define the optimal post‐transplant pathways. Explant‐beyond‐criteria HCC represents a distinct high‐risk population that requires individualized post‐transplant management. While no validated adjuvant therapy exists, risk stratification using tools such as the RETREAT score, immunosuppression optimization with mammalian target of rapamycin (mTOR) inhibitors, and intensified surveillance may improve outcomes. Prospective studies are needed to define the optimal management strategies for this challenging population.
- Open Access
- 6 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 830-839
Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.
- 6 August 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 830-839
Open AccessPerioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors
Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.
- 22 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117124
Impact of neoadjuvant chemotherapy on postoperative outcomes in intrahepatic cholangiocarcinoma: A propensity-matched analysis
- 22 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117124
Impact of neoadjuvant chemotherapy on postoperative outcomes in intrahepatic cholangiocarcinoma: A propensity-matched analysis
- 4 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117093
Factors associated with mortality in pancreatic adenocarcinoma patients achieving pathologic complete response after neoadjuvant therapy
- 4 June 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260, 117093
Factors associated with mortality in pancreatic adenocarcinoma patients achieving pathologic complete response after neoadjuvant therapy
- Open Access
- 1 June 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (2) , 157-165
Management of Satellite Lesions in Hepatocellular Carcinoma: An Updated Review
Satellite lesions, defined as microscopic or small macroscopic tumor nodules within 2 cm of a primary hepatocellular carcinoma (HCC), represent early intrahepatic dissemination and are strongly associated with aggressive tumor biology. This review synthesizes the current evidence regarding the biological basis, diagnostic challenges, prognostic relevance, and therapeutic approaches for managing satellite lesions in HCC. In published studies, satellite lesions were consistently linked to aggressive tumor behavior, including higher rates of microvascular invasion, multifocality, and early postoperative recurrence. Patients with satellite lesions experienced significantly reduced disease‐free and overall survival compared to those with solitary tumors, although outcomes varied with tumor size, number, and liver function. In transplant‐eligible cohorts, satellite lesions were associated with exceeding standard listing criteria and demonstrated increased post‐transplant recurrence when identified on explant pathology. Radiologic detection showed moderate sensitivity but high specificity, influencing selection for resection, ablation, and transplant‐based strategies. Satellite lesions are a critical marker of tumor aggressiveness in HCC and significantly influence surgical and transplant decision‐making. Although resection may be appropriate for carefully selected patients with preserved liver function, recurrence rates remain high. The presence or suspicion of satellite lesions strongly impacts transplant candidacy, with most guidelines considering radiological satellites an indicator of advanced disease.
- 1 June 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (2) , 157-165
Open AccessManagement of Satellite Lesions in Hepatocellular Carcinoma: An Updated Review
Satellite lesions, defined as microscopic or small macroscopic tumor nodules within 2 cm of a primary hepatocellular carcinoma (HCC), represent early intrahepatic dissemination and are strongly associated with aggressive tumor biology. This review synthesizes the current evidence regarding the biological basis, diagnostic challenges, prognostic relevance, and therapeutic approaches for managing satellite lesions in HCC. In published studies, satellite lesions were consistently linked to aggressive tumor behavior, including higher rates of microvascular invasion, multifocality, and early postoperative recurrence. Patients with satellite lesions experienced significantly reduced disease‐free and overall survival compared to those with solitary tumors, although outcomes varied with tumor size, number, and liver function. In transplant‐eligible cohorts, satellite lesions were associated with exceeding standard listing criteria and demonstrated increased post‐transplant recurrence when identified on explant pathology. Radiologic detection showed moderate sensitivity but high specificity, influencing selection for resection, ablation, and transplant‐based strategies. Satellite lesions are a critical marker of tumor aggressiveness in HCC and significantly influence surgical and transplant decision‐making. Although resection may be appropriate for carefully selected patients with preserved liver function, recurrence rates remain high. The presence or suspicion of satellite lesions strongly impacts transplant candidacy, with most guidelines considering radiological satellites an indicator of advanced disease.